Volume 11, Issue 44 (9-2021)                   NCMBJ 2021, 11(44): 57-70 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohseni M, Dehghani Ashkezari M, Akhlaghi M, Ansari K, Haghirosadat B F. A new therapeutic approach for the treatment of breast cancer using synthesis of liposomes containing silybinin and their characterization. NCMBJ. 2021; 11 (44) :57-70
URL: http://ncmbjpiau.ir/article-1-1417-en.html
Medical Biotechnology Researching Center, Islamic Azad University, Ashkezar Branch, Yazd, Iran
Abstract:   (561 Views)
Aim and Background: Silybinin, one of the active pharmaceutical ingredients in some medical herbs, has been proven to have anti-cancer effects. The aim of this study was to synthesis and characterize lipid nano-carriers containing silybinin in order to breast cancer treatment.
Material and Methods: Lipid nanocarriers were synthesized using a thin film method and the drug was loaded on them. Then the physicochemical properties were evaluated using DLS, AFM and spectrophotometers and their toxicity was measured in comparison with the free form of the drug by MTT assay on BT-474 breast cancer cell line.
Results: The synthesized nano-system with a size of 113.2 nm, zeta potential of -22 ± 1.63 mV, slow release type with appropriate physicochemical properties improves the anti-cancer effects of drug on breast cancer cells.
Conclusion: The results of this study demonstrated that the synthesized system, in addition to having appropriate physicochemical properties, could improve anti-cancer effect of drug.
Full-Text [PDF 799 kb]   (92 Downloads) |   |   Full-Text (HTML)  (176 Views)  
Type of Study: Research Article | Subject: Biochemistry
Received: 2021/09/11 | Accepted: 2021/09/1 | Published: 2021/09/1

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | New Cellular and Molecular Biotechnology Journal

Designed & Developed by : Yektaweb